AIM:To evaluate the efficacy of Seprafilm transplantation following adhesiolysis for preventing postoperative readhesion and improving surgical outcomes. METHODS:Primary blepharoplasty was carried out on both eyelids ...AIM:To evaluate the efficacy of Seprafilm transplantation following adhesiolysis for preventing postoperative readhesion and improving surgical outcomes. METHODS:Primary blepharoplasty was carried out on both eyelids of 18 albino rabbits. After 2 weeks, a new skin incision was made, and adhesiolysis was performed on both eyelids. The rabbits were categorized into two groups, one with adhesiolysis alone in the left eyelid (control group), and the other with adhesiolysis with a Seprafilm graft in the right eyelid (Seprafilm group). The degrees of inflammation and fibrosis were examined with hematoxylin-eosin (HE) and Masson’s trichrome stains. Expression of α-smooth muscle actin (α-SMA) was also immunohistochemically examined. RESULTS:Eyelid examination immediately after the operation revealed mild swelling and hemorrhage in both groups, but these symptoms resolved after 1 week-2 weeks, and eyelid shape had recovered completely in both groups. Microscopic assessments demonstrated that the Seprafilm group showed less inflammation and fibrosis than the control group. The Seprafilm group also exhibited fewer α-SMA-positive cells than the control group. CONCLUSION:Based on these findings, we conclude that Seprafilm graft with adhesiolysis is an effective method for preventing postoperative readhesions after eyelid surgery.展开更多
Due to the recent advances in assisted reproductive technology therapy and perinatal care, cesarean sections have been increasingly employed. The aim of this study was to elucidate the effectiveness of Seprafilm<sp...Due to the recent advances in assisted reproductive technology therapy and perinatal care, cesarean sections have been increasingly employed. The aim of this study was to elucidate the effectiveness of Seprafilm<span style="white-space:nowrap;"><sup>®</sup></span> in saving time during fetal deliveries and in minimizing the amount of blood loss in cesarean deliveries. In cases of second cesarean section, our results showed that Seprafilm<span style="white-space:nowrap;"><sup>®</sup></span> significantly reduced the fetal delivery time from 7.5 ±<span><span><span style="font-family:;" "=""> </span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">2.8 to 5.4 ±</span></span></span><span><span><span style="font-family:;" "=""> </span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">2.2 min (p = 0.001). The time required for total surgery was shortened from 45.3</span></span></span><span><span><span style="font-family:;" "=""> </span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">±</span></span></span><span><span><span style="font-family:;" "=""> </span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">10.0 to 39.6 ±</span></span></span><span><span><span style="font-family:;" "=""> </span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">6.5 min (p = 0.003). The blood loss was diminished from 816.4</span></span></span><span><span><span style="font-family:;" "=""> </span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">±</span></span></span><span><span><span style="font-family:;" "=""> </span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">352.1 to 630.8 ± 255.9 g (p = 0.01). These results demonstrate that Seprafilm<span style="white-space:nowrap;"><sup>®</sup></span> is very effective even in repeated cesarean sections.</span></span></span>展开更多
Background: The safety and efficacy of Seprafilm (Genzyme Corporation, Cambrid ge, Mass) in adult surgery patients have been established. The aim of this study was to evaluate the safety and efficacy of Seprafilm in p...Background: The safety and efficacy of Seprafilm (Genzyme Corporation, Cambrid ge, Mass) in adult surgery patients have been established. The aim of this study was to evaluate the safety and efficacy of Seprafilm in pediatric surgical pati ents. Methods: One hundred twenty-two pediatric abdominal surgery patients were enrolled. Sixty-seven patients received Seprafilm application. Of these patien ts, 18 again received Seprafilm at abdominal closure during a second surgery, an d of the 18, 4 received Seprafilm at closure after a third surgery. Of the 55 co ntrol patients who did not receive Seprafilm, 14 had a second surgery, and of th ese 14 patients, 4 had a third surgery. Adverse events, operation time, and bloo d loss were compared with assessed Seprafilm safety. Seprafilm efficacy evaluati ons included incidence and severity of adhesions in those patients who required relaparotomy. Results: The incidence (Seprafilm, 40.9%; control, 82.4%) and se verity (Seprafilm: 59.1%, grade 0; control: 17.6%, grade 0) of adhesions under the abdominal incision site were significantly reduced in the Seprafilm group ( P = .007 and P = .0009, respectively). In addition, mean relaparotomy operation time was significantly shorter for Seprafilmpatients (P = .004). At relaparotomy , blood loss/body weight ratio for Seprafilm patients compared with control pati ents showed a trend toward but did not reach significance (P = .09). Conclusions : Decreased incidence and severity of postsurgical adhesions with Seprafilmin pe diatric patientsmay lead to reduction of the risks associated with subsequent op eration.展开更多
基金Supported by the Dong-A University Research Fund
文摘AIM:To evaluate the efficacy of Seprafilm transplantation following adhesiolysis for preventing postoperative readhesion and improving surgical outcomes. METHODS:Primary blepharoplasty was carried out on both eyelids of 18 albino rabbits. After 2 weeks, a new skin incision was made, and adhesiolysis was performed on both eyelids. The rabbits were categorized into two groups, one with adhesiolysis alone in the left eyelid (control group), and the other with adhesiolysis with a Seprafilm graft in the right eyelid (Seprafilm group). The degrees of inflammation and fibrosis were examined with hematoxylin-eosin (HE) and Masson’s trichrome stains. Expression of α-smooth muscle actin (α-SMA) was also immunohistochemically examined. RESULTS:Eyelid examination immediately after the operation revealed mild swelling and hemorrhage in both groups, but these symptoms resolved after 1 week-2 weeks, and eyelid shape had recovered completely in both groups. Microscopic assessments demonstrated that the Seprafilm group showed less inflammation and fibrosis than the control group. The Seprafilm group also exhibited fewer α-SMA-positive cells than the control group. CONCLUSION:Based on these findings, we conclude that Seprafilm graft with adhesiolysis is an effective method for preventing postoperative readhesions after eyelid surgery.
文摘Due to the recent advances in assisted reproductive technology therapy and perinatal care, cesarean sections have been increasingly employed. The aim of this study was to elucidate the effectiveness of Seprafilm<span style="white-space:nowrap;"><sup>®</sup></span> in saving time during fetal deliveries and in minimizing the amount of blood loss in cesarean deliveries. In cases of second cesarean section, our results showed that Seprafilm<span style="white-space:nowrap;"><sup>®</sup></span> significantly reduced the fetal delivery time from 7.5 ±<span><span><span style="font-family:;" "=""> </span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">2.8 to 5.4 ±</span></span></span><span><span><span style="font-family:;" "=""> </span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">2.2 min (p = 0.001). The time required for total surgery was shortened from 45.3</span></span></span><span><span><span style="font-family:;" "=""> </span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">±</span></span></span><span><span><span style="font-family:;" "=""> </span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">10.0 to 39.6 ±</span></span></span><span><span><span style="font-family:;" "=""> </span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">6.5 min (p = 0.003). The blood loss was diminished from 816.4</span></span></span><span><span><span style="font-family:;" "=""> </span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">±</span></span></span><span><span><span style="font-family:;" "=""> </span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">352.1 to 630.8 ± 255.9 g (p = 0.01). These results demonstrate that Seprafilm<span style="white-space:nowrap;"><sup>®</sup></span> is very effective even in repeated cesarean sections.</span></span></span>
文摘Background: The safety and efficacy of Seprafilm (Genzyme Corporation, Cambrid ge, Mass) in adult surgery patients have been established. The aim of this study was to evaluate the safety and efficacy of Seprafilm in pediatric surgical pati ents. Methods: One hundred twenty-two pediatric abdominal surgery patients were enrolled. Sixty-seven patients received Seprafilm application. Of these patien ts, 18 again received Seprafilm at abdominal closure during a second surgery, an d of the 18, 4 received Seprafilm at closure after a third surgery. Of the 55 co ntrol patients who did not receive Seprafilm, 14 had a second surgery, and of th ese 14 patients, 4 had a third surgery. Adverse events, operation time, and bloo d loss were compared with assessed Seprafilm safety. Seprafilm efficacy evaluati ons included incidence and severity of adhesions in those patients who required relaparotomy. Results: The incidence (Seprafilm, 40.9%; control, 82.4%) and se verity (Seprafilm: 59.1%, grade 0; control: 17.6%, grade 0) of adhesions under the abdominal incision site were significantly reduced in the Seprafilm group ( P = .007 and P = .0009, respectively). In addition, mean relaparotomy operation time was significantly shorter for Seprafilmpatients (P = .004). At relaparotomy , blood loss/body weight ratio for Seprafilm patients compared with control pati ents showed a trend toward but did not reach significance (P = .09). Conclusions : Decreased incidence and severity of postsurgical adhesions with Seprafilmin pe diatric patientsmay lead to reduction of the risks associated with subsequent op eration.
